GYNISUS

Company Overview

Snapshot

Founded in January 2017 by Hila Friedmann, Zoya Gordon, and Israel Meizner, GYNISUS operated with 11–50 employees. The company secured $50,000 in total capital across three funding rounds from three investors. In March 2023, Plug and Play led a Seed funding round.

Business overview

GYNISUS leveraged artificial intelligence to enhance diagnosis and treatment processes within the healthcare sector. Its core offering, the SPAI platform, delivered intelligent insights and predictions, aiming to improve patient care by identifying individuals at higher risk for complications and disease. The platform also supported better forecasting for resource utilization and cost management. GYNISUS's Infectious Disease Intelligence Platform, powered by SPAI, was implemented in medical centers in New York to help identify individuals likely to be infected with viruses like COVID-19 and their contacts, serving hospitals, home nursing facilities, and senior living centers. The company operated within the Digital Healthcare, Digital Medical Diagnostics, and Medical Decision Support sectors, targeting healthcare providers and women.

Company Intelligence Q&A

What is the current operational status of GYNISUS?

GYNISUS ceased to operate in August 2024.

When was GYNISUS founded and by whom?

GYNISUS was founded in January 2017 by co-founders Hila Friedmann, Zoya Gordon, and Israel Meizner.

What was the total capital raised by GYNISUS?

GYNISUS raised a total of $50,000 across three funding rounds.